Evaluation of the Effect of Streptococcus Salivarius K12 Probiotic in the Treatment of Periodontitis

Not Applicable

Completed

• Conditions: Periodontitis Stage III; Probiotic

• Registration Number: NCT06871540
• Lead Sponsor: AYŞENUR ŞAHİN

Brief Summary

Aims: The use of oral probiotics as an adjunct to the treatment of periodontal diseases is known to be beneficial in antagonizing pathogenic microflora and regulating the host immune response. The aim of this clinical study was to evaluate the clinical, microbiologic and biochemical effect of Streptococcus salivarius (S. salivarius) K12 probiotic tablet as an adjunct to scaling and root planing (SRP) treatment in stage 3 periodontitis patients.

Methods: The study included 30 systemically healthy stage 3 periodontitis patients. After non-surgical periodontal treatment, participants were randomly assigned to the test (SRP+Probiotic, n=15) or control (SRP, n=15) group. Patients in the test group used probiotic tablets once daily for 30 days. Clinical (Plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL)), microbiological (Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Prevotella intermedia, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum) and biochemical (IL-6, IL-8, IL-10) measurements were performed at baseline (before SRP), 30. and 90th days. Data were analyzed statistically.

Keywords: Microbiology, Periodontitis, Probiotics, Cytokines

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-01
• Primary Completion: 2024-06-30
• Study Completion: 2024-06-30
• Status Verified: 2025-03
• Study First Submitted: 2025-03-06
• Study First Submitted QC: 2025-03-11
• Last Update Submitted: 2025-03-11
• Study First Posted: 2025-03-12
• Last Update Posted: 2025-03-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Male or female aged 18-60 years,
• No systemic disease,
• No periodontal treatment in the last 6 months,
• No antibiotic therapy in the last 6 months,
• Diagnosed with stage 3 periodontitis according to the 2017 periodontal disease classification

Exclusion Criteria

• Periodontal treatment within sixteen months,
• Smoking,
• Patients with systemic health problems such as diabetes, rheumatoid arthritis, neurological diseases, lung and kidney diseases,
• Pregnancy or lactation,
• Acute oral lesions or necrotizing ulcerative periodontitis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Reduction in Porphyromonas gingivalis at 3 months	From enrollment to the end of treatment at 12 weeks

Trial Locations

Locations (1)

İnönü Üniversitesi Diş Hekimliği Fakültesi; 🇹🇷 Malatya, Battalgazi, Turkey